Recent
studies have shown that nuclear transcription factor cyclic
adenosine monophosphate response element binding protein (CREB) is
overexpressed in many different types of cancers. Therefore, CREB
has been pursued as a novel cancer therapeutic target. Naphthol AS-E
and its closely related derivatives have been shown to inhibit CREB-mediated
gene transcription and cancer cell growth. Previously, we identified
naphthamide 3a as a different chemotype to inhibit CREB’s
transcription activity. In a continuing effort to discover more potent
CREB inhibitors, a series of structural congeners of 3a was designed and synthesized. Biological evaluations of these compounds
uncovered compound 3i (666-15) as a potent
and selective inhibitor of CREB-mediated gene transcription (IC50 = 0.081 ± 0.04 μM). 666-15 also
potently inhibited cancer cell growth without harming normal cells.
In an in vivo MDA-MB-468 xenograft model, 666-15 completely
suppressed the tumor growth without overt toxicity. These results
further support the potential of CREB as a valuable cancer drug target.
Background: HIF1␣ is a target of anticancer therapy. Results: Lysines within the HIF1␣ N terminus are targets of HDAC4 deacetylation. HDAC4 inhibition causes the increase of HIF1␣ protein acetylation and decrease of protein stability, which lead to the reduction of HIF-1-mediated target gene expressions and activities in cancer cells. Conclusion: HDAC4 provides a novel HIF1␣ regulatory mechanism. Significance: HIF-1 can be targeted by HDAC4 inhibition.
Background: HIF1␣ and p300 are key components of HIF-1 transcription complex. Results: Lysine 709 of HIF1␣ is acetylated by p300, which increases protein stability and HIF-1 activity. Conclusion: p300 has a novel function in stabilizing HIF1␣ by Lys-709 acetylation. Significance: New insights in how HIF1␣ is post-translationally regulated by its cofactor to ensure HIF-1 activity.
During the reproductive cycle, fluctuations in circulating estrogens affect multiple homeostatic systems controlled by hypothalamic neurons. Two of these neuronal populations are arcuate proopiomelanocortin and neuropeptide Y neurons, which control energy homeostasis and feeding. Estradiol modulates these neurons either through the classical estrogen receptors (ERs) to control gene transcription or through a G protein-coupled receptor (mER) activating multiple signaling pathways. To differentiate between these two divergent ER-mediated mechanisms and their effects on homeostasis, female guinea pigs were ovariectomized and treated systemically with vehicle, estradiol benzoate (EB) or STX, a selective mER agonist, for 4 wk, starting 7 d after ovariectomy. Individual body weights were measured after each injection day for 28 d, at which time the animals were euthanized, and the arcuate nucleus was microdissected. As predicted, the body weight gain was significantly lower for EB-treated females after d 5 and for STX-treated females after d 12 compared with vehicle-treated females. Total arcuate RNA was extracted from all groups, but only the vehicle and STX-treated samples were prepared for gene microarray analysis using a custom guinea pig gene microarray. In the arcuate nucleus, 241 identified genes were significantly regulated by STX, several of which were confirmed by quantitative real-time PCR and compared with EB-treated groups. The lower weight gain of EB-treated and STX-treated females suggests that estradiol controls energy homeostasis through both ERalpha and mER-mediated mechanisms. Genes regulated by STX indicate that not only does it control neuronal excitability but also alters gene transcription via signal transduction cascades initiated from mER activation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.